Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 3/20 | 0.42 |
| ▸ | PDE9A | O76083 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 6/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | GOT1 | P17174 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24352277 | 0.85 | LTA4H (0.45) | CASP6PDE9AHTR2CHTR2AROCK2 | |
| SCHEMBL24352816 | 0.81 | CASP6 (0.39) | CASP6PDE9AHTR2CHTR2AROCK2 | |
| SCHEMBL24352663 | 0.79 | DPP4 (0.47) | CASP6PDE9AHTR2CHTR2AGOT1 | |
| Hydrochloric Acid SCHEMBL29473282 | 0.77 | DPP4 (0.46) | CASP6PDE9AHTR2CHTR2AGOT1 | |
| SCHEMBL28680308 | 0.76 | HTR2C (0.40) | CASP6PDE9AHTR2CHTR2AHTR2B | |
| SCHEMBL24352771 | 0.72 | KCNA5 (0.51) | KCNA5 | |
| SCHEMBL24352629 | 0.72 | CYP1A2 (0.35) | — | |
| SCHEMBL8138036 | 0.68 | IDO1 (0.44) | CASP6HTR2CHTR2A | |
| SCHEMBL3464878 | 0.68 | NPC1 (0.45) | HTR2CHTR2A | |
| SCHEMBL10765944 | 0.68 | IDO1 (0.46) | HTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119395-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119395-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | CASP6 2981/4885PDE9A 614/4885HTR2C 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.